regmedjournalРегенерация органов и тканейРегенерация органов и тканей2949-5938Общество регенеративной медицины10.60043/2949-5938-2023-1-16-24regmedjournal-4Research ArticleОБЗОРЫ И КОММЕНТАРИИREVIEWS AND COMMENTSТри десятилетия развития генной терапии: вехи и перспективыThree decades of gene therapy development: milestones and prospectsМакаревичП. И.MakarevichP. I.

Макаревич Павел Игоревич — к.м.н., зав. лабораторией генно-клеточной терапии, Институт регенеративной медицины Медицинского научно-образовательного центра; доцент кафедры биохимии и молекулярной медицины Факультета фундаментальной медицины

119192, г. Москва, Ленинские горы, 1

Pavel. I. Makarevich — MD, PhD, Head of Gene and Cell Therapy Laboratory, Institute for Regenerative Medicine, Medical Research and Education Center; assistant professor at Department of Biochemistry and Molecular Medicine, Faculty of Medicine

119192, Moscow, Leninskiye Gory, 1

makarevichpi@my.msu.ruФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian Federation202331052023111624Copyright © Макаревич П.И., 20232023Макаревич П.И.Makarevich P.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.regmed-journal.ru/jour/article/view/4

За тридцать лет развития с момента первого применения в клинике генная терапия (ГТ) прошла путь от экспериментального направления до наиболее активно развивающейся области современной биомедицины. Значительные успехи чередовались в течение этого периода с резкими спадами, и именно они вкупе с новыми идеями сформировали основные вехи, которым посвящено данное сообщение. Анализ накопленного опыта формирует направления, лежит в основе открывающихся перспектив развития ГТ и задает вектор для их реализации. При этом нельзя не забывать и о важных вопросах этичности и безопасности, которые являются краеугольными камнями, поддерживающими возможность применения методов ГТ у человека. Настоящее сообщение кратко суммирует наиболее важные события и фундаментальные положения, которые сформировали современный облик ГТ, излагает ее перспективы и проблемные вопросы, которые стоят перед областью в настоящее время.

Within past 30 years of progress since its first clinical use, gene therapy (GT) has gone from an experimental field to the most actively developing area of modern biomedicine. Significant advances during this period were mixed with sharp declines, and this pathway taken together with new ideas and concepts has formed the main milestones which this short review addresses. Analysis of accumulated experience provides directions, makes up for emerging prospects for the development of GT and sets the vector for their implementation. At the same time, we should not forget about the crucial issues of ethics and safety, which are the cornerstones supporting the use of GT in human. This report briefly summarizes the most important events and fundamental provisions that have shaped the modern landscape of GT, outlines its prospects and problematic issues in the field.

генная терапиявекторнаследственные заболеванияплазмидавирусный векторgene therapyvectorhereditary diseasesplasmidviral vectorРабота выполнена в рамках государственного задания МГУ имени М.В. Ломоносова и по перспективному направлению научно-образовательного развития Московского университета «Молекулярные технологии живых систем и синтетическая биология».The work was carried under state assignment of M.V. Lomonosov Moscow State University and the prospective direction of scientific and educational development of M.V. Lomonosov Moscow State University “Molecular technologies of living systems and synthetic biology”.ReferencesAnguela X.M., High K.A. Entering the Modern Era of Gene Therapy. Annu Rev Med. 2019;70:273–288.Anguela X.M., High K.A. Entering the Modern Era of Gene Therapy. Annu Rev Med. 2019;70:273–288.Bulaklak K., Gersbach C.A. The once and future gene therapy. Nat Commun. 2020;11(1):5820.Bulaklak K., Gersbach C.A. The once and future gene therapy. Nat Commun. 2020;11(1):5820.Papanikolaou E., Bosio A. The Promise and the Hope of Gene Therapy. Front Genome Ed. 2021;3:618346.Papanikolaou E., Bosio A. The Promise and the Hope of Gene Therapy. Front Genome Ed. 2021;3:618346.Friedmann T., Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025): 949–955.Friedmann T., Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025): 949–955.Salmikangas P., Schuessler-Lenz M., Ruiz S., Celis P., Reischl I., Menezes-Ferreira M., et al. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Adv Exp Med Biol. 2015;871:103–130.Salmikangas P., Schuessler-Lenz M., Ruiz S., Celis P., Reischl I., Menezes-Ferreira M., et al. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Adv Exp Med Biol. 2015;871:103–130.Somia N., Verma I.M. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1(2):91–99.Somia N., Verma I.M. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1(2):91–99.Naso M.F., Tomkowicz B., Perry W.L., 3rd, Strohl W.R. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31(4):317–334.Naso M.F., Tomkowicz B., Perry W.L., 3rd, Strohl W.R. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31(4):317–334.Lukashev A.N., Zamyatnin A.A., Jr. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. Biochemistry (Mosc). 2016;81(7):700–708.Lukashev A.N., Zamyatnin A.A., Jr. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. Biochemistry (Mosc). 2016;81(7):700–708.Anderson W.F. Human gene therapy. Science. 1992;256(5058):808–813.Anderson W.F. Human gene therapy. Science. 1992;256(5058):808–813.Bulcha J.T., Wang Y., Ma H., Tai P.W.L., Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53.Bulcha J.T., Wang Y., Ma H., Tai P.W.L., Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53.Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Applied Biosafety. 2020;25(1):7–18.Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Applied Biosafety. 2020;25(1):7–18.Shahryari A., Saghaeian Jazi M., Mohammadi S., Razavi Nikoo H., Nazari Z., Hosseini E.S., et al. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Front Genet. 2019;10:868.Shahryari A., Saghaeian Jazi M., Mohammadi S., Razavi Nikoo H., Nazari Z., Hosseini E.S., et al. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Front Genet. 2019;10:868.Karagyaur M., Efimenko A., Makarevich P., Akopyan Z., Bryzgalina E., Tkachuk V. Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review). Sovremennye tehnologii v medicine. 2019;11.Karagyaur M., Efimenko A., Makarevich P., Akopyan Z., Bryzgalina E., Tkachuk V. Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review). Sovremennye tehnologii v medicine. 2019;11.Arabi F., Mansouri V., Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324.Arabi F., Mansouri V., Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324.De Haro J., Acin F., Lopez-Quintana A., Florez A., Martinez-Aguilar E., Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels. 2009;24(5):321–328.De Haro J., Acin F., Lopez-Quintana A., Florez A., Martinez-Aguilar E., Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels. 2009;24(5):321–328.Ilieva K., Borissov B., Toumi M. Gene therapy randomised clinical trials in Europe — a review paper of methodology and design. J Mark Access Health Policy. 2020;8(1):1847808.Ilieva K., Borissov B., Toumi M. Gene therapy randomised clinical trials in Europe — a review paper of methodology and design. J Mark Access Health Policy. 2020;8(1):1847808.Karagyaur M., Rostovtseva A., Semina E., Klimovich P., Balabanyan V., Makarevich P., et al. A Bicistronic Plasmid Encoding Brain-Derived Neurotrophic Factor and Urokinase Plasminogen Activator Stimulates Peripheral Nerve Regeneration After Injury. J Pharmacol Exp Ther. 2020;372(3):248–255.Karagyaur M., Rostovtseva A., Semina E., Klimovich P., Balabanyan V., Makarevich P., et al. A Bicistronic Plasmid Encoding Brain-Derived Neurotrophic Factor and Urokinase Plasminogen Activator Stimulates Peripheral Nerve Regeneration After Injury. J Pharmacol Exp Ther. 2020;372(3):248–255.Slobodkina E., Boldyreva M., Karagyaur M., Eremichev R., Alexandrushkina N., Balabanyan V., et al. Therapeutic Angiogenesis by a “Dynamic Duo”: Simultaneous Expression of HGF and VEGF165 by Novel Bicistronic Plasmid Restores Blood Flow in Ischemic Skeletal Muscle. Pharmaceutics. 2020;12(12):1231.Slobodkina E., Boldyreva M., Karagyaur M., Eremichev R., Alexandrushkina N., Balabanyan V., et al. Therapeutic Angiogenesis by a “Dynamic Duo”: Simultaneous Expression of HGF and VEGF165 by Novel Bicistronic Plasmid Restores Blood Flow in Ischemic Skeletal Muscle. Pharmaceutics. 2020;12(12):1231.Kessler J.A., Shaibani A., Sang C.N., Christiansen M., Kudrow D., Vinik A., et al. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14(3):1176–1184.Kessler J.A., Shaibani A., Sang C.N., Christiansen M., Kudrow D., Vinik A., et al. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14(3):1176–1184.Touchard E., Benard R., Bigot K., Laffitte J.D., Buggage R., Bordet T., et al. Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product. J Control Release. 2018;285:244–251.Touchard E., Benard R., Bigot K., Laffitte J.D., Buggage R., Bordet T., et al. Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product. J Control Release. 2018;285:244–251.Stenler S., Blomberg P., Smith C.I. Safety and efficacy of DNA vaccines: plasmids vs. minicircles. Hum Vaccin Immunother. 2014;10(5):1306–1308.Stenler S., Blomberg P., Smith C.I. Safety and efficacy of DNA vaccines: plasmids vs. minicircles. Hum Vaccin Immunother. 2014;10(5):1306–1308.Bozo I.Y., Drobyshev A.Y., Redko N.A., Komlev V.S., Isaev A.A., Deev R.V. Bringing a Gene-Activated Bone Substitute Into Clinical Practice: From Bench to Bedside. Front Bioeng Biotechnol. 2021;9:599300.Bozo I.Y., Drobyshev A.Y., Redko N.A., Komlev V.S., Isaev A.A., Deev R.V. Bringing a Gene-Activated Bone Substitute Into Clinical Practice: From Bench to Bedside. Front Bioeng Biotechnol. 2021;9:599300.Астапова О.В., Берчатова А.А. Генотерапевтические препараты: аспекты доклинического изучения безопасности. Безопасность и риск фармакотерапии. 2023;11(1):73–96.Астапова О.В., Берчатова А.А. Генотерапевтические препараты: аспекты доклинического изучения безопасности. Безопасность и риск фармакотерапии. 2023;11(1):73–96.Makarevich P., Tsokolaeva Z., Shevelev A., Rybalkin I., Shevchenko E., Beloglazova I., et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One. 2012;7(6):e38776.Makarevich P., Tsokolaeva Z., Shevelev A., Rybalkin I., Shevchenko E., Beloglazova I., et al. Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One. 2012;7(6):e38776.Makarevich P.I., Dergilev K.V., Tsokolaeva Z.I., Boldyreva M.A., Shevchenko E.K., Gluhanyuk E.V., et al. Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS One. 2018;13(5):e0197566.Makarevich P.I., Dergilev K.V., Tsokolaeva Z.I., Boldyreva M.A., Shevchenko E.K., Gluhanyuk E.V., et al. Angiogenic and pleiotropic effects of VEGF165 and HGF combined gene therapy in a rat model of myocardial infarction. PLoS One. 2018;13(5):e0197566.Masgutov R., Zeinalova A., Bogov A., Masgutova G., Salafutdinov I., Garanina E., et al. Angiogenesis and nerve regeneration induced by local administration of plasmid pBud-coVEGF165- coFGF2 into the intact rat sciatic nerve. Neural Regen Res. 2021;16(9):1882–1889.Masgutov R., Zeinalova A., Bogov A., Masgutova G., Salafutdinov I., Garanina E., et al. Angiogenesis and nerve regeneration induced by local administration of plasmid pBud-coVEGF165- coFGF2 into the intact rat sciatic nerve. Neural Regen Res. 2021;16(9):1882–1889.Boldyreva Mcapital A.C., Bondar I.V., Stafeev I.S., Makarevich P.I., Beloglazova I.B., Zubkova E.S., et al. Plasmid-based gene therapy with hepatocyte growth factor stimulates peripheral nerve regeneration after traumatic injury. Biomed Pharmacother. 2018;101:682–690.Boldyreva Mcapital A.C., Bondar I.V., Stafeev I.S., Makarevich P.I., Beloglazova I.B., Zubkova E.S., et al. Plasmid-based gene therapy with hepatocyte growth factor stimulates peripheral nerve regeneration after traumatic injury. Biomed Pharmacother. 2018;101:682–690.Idrisova K.F., Zeinalova A.K., Masgutova G.A., Bogov A.A., Allegrucci C., Syromiatnikova V.Y., et al. Application of neurotrophic and proangiogenic factors as therapy after peripheral nervous system injury. Neural Regen Res. 2022;17(6):1240–1247.Idrisova K.F., Zeinalova A.K., Masgutova G.A., Bogov A.A., Allegrucci C., Syromiatnikova V.Y., et al. Application of neurotrophic and proangiogenic factors as therapy after peripheral nervous system injury. Neural Regen Res. 2022;17(6):1240–1247.Karagyaur M., Dyikanov D., Makarevich P., Semina E., Stambolsky D., Plekhanova O., et al. Non-viral transfer of BDNF and uPA stimulates peripheral nerve regeneration. Biomed Pharmacother. 2015;74:63–70.Karagyaur M., Dyikanov D., Makarevich P., Semina E., Stambolsky D., Plekhanova O., et al. Non-viral transfer of BDNF and uPA stimulates peripheral nerve regeneration. Biomed Pharmacother. 2015;74:63–70.Iyer A.A., Groves A.K. Transcription Factor Reprogramming in the Inner Ear: Turning on Cell Fate Switches to Regenerate Sensory Hair Cells. Front Cell Neurosci. 2021;15:660748.Iyer A.A., Groves A.K. Transcription Factor Reprogramming in the Inner Ear: Turning on Cell Fate Switches to Regenerate Sensory Hair Cells. Front Cell Neurosci. 2021;15:660748.Todd L., Hooper M.J., Haugan A.K., Finkbeiner C., Jorstad N., Radulovich N., et al. Efficient stimulation of retinal regeneration from Muller glia in adult mice using combinations of proneural bHLH transcription factors. Cell Rep. 2021;37(3):109857.Todd L., Hooper M.J., Haugan A.K., Finkbeiner C., Jorstad N., Radulovich N., et al. Efficient stimulation of retinal regeneration from Muller glia in adult mice using combinations of proneural bHLH transcription factors. Cell Rep. 2021;37(3):109857.Tung A., Levin M. Extra-genomic instructive influences in morphogenesis: A review of external signals that regulate growth and form. Dev Biol. 2020;461(1):1–12.Tung A., Levin M. Extra-genomic instructive influences in morphogenesis: A review of external signals that regulate growth and form. Dev Biol. 2020;461(1):1–12.Reichert M., Takano S., von Burstin J., Kim S.B., Lee J.S., Ihida-Stansbury K., et al. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev. 2013;27(3):288–300.Reichert M., Takano S., von Burstin J., Kim S.B., Lee J.S., Ihida-Stansbury K., et al. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev. 2013;27(3):288–300.

The authors declare that there are no conflicts of interest present.